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Inhibition of EZH2 Ameliorates Lupus- Like Disease in 
MRL/lpr Mice
Dallas M. Rohraff,1 Ye He,2 Evan A. Farkash,1 Mark Schonfeld,1 Pei-Suen Tsou,1 and Amr H. Sawalha3
Objective. We previously identified a role for EZH2, a transcriptional regulator in inducing proinflammatory epige-
netic changes in lupus CD4+ T cells. This study was undertaken to investigate whether inhibiting EZH2 ameliorates 
lupus- like disease in MRL/lpr mice.
Methods. EZH2 expression levels in multiple cell types in lupus patients were evaluated using flow cytome-
try and messenger RNA expression data. Inhibition of EZH2 in MRL/lpr mice was achieved by intraperitoneal 
3′- deazaneplanocin (DZNep) administration using a preventative and a therapeutic treatment model. Effects of DZNep 
on animal survival, anti–double- stranded DNA (anti- dsDNA) antibody production, proteinuria, renal histopathology, 
cytokine production, and T and B cell numbers and percentages were assessed.
Results. EZH2 expression levels were increased in whole blood, neutrophils, monocytes, B cells, and CD4+ T cells 
in lupus patients. In MRL/lpr mice, inhibition of EZH2 by DZNep was confirmed by significant reduction of EZH2 and 
H3K27me3 in splenocytes. Inhibiting EZH2 with DZNep treatment before or after disease onset improved survival and 
significantly reduced anti- dsDNA antibody production. DZNep- treated mice displayed a significant reduction in re-
nal involvement, splenomegaly, and lymphadenopathy. Lymphoproliferation and numbers of double- negative T cells 
were significantly reduced in DZNep- treated mice. Concentrations of circulating cytokines and chemokines, including 
tumor necrosis factor, interferon- γ, CCL2, RANTES/CCL5, interleukin- 10 (IL- 10), keratinocyte- derived chemokine/
CXCL1, IL- 12, IL- 12p40, and CCL4/macrophage inflammatory protein 1β, were decreased in DZNep- treated mice.
Conclusion. EZH2 is up- regulated in multiple cell types in lupus patients. Therapeutic inhibition of EZH2 abro-
gates lupus- like disease in MRL/lpr mice, suggesting that EZH2 inhibitors may be repurposed as a novel therapeutic 
option for lupus patients.
INTRODUCTION
Systemic lupus erythematosus (SLE), or lupus, is a chronic 
relapsing autoimmune disease that involves multiple organ 
systems. Lupus is characterized by the production of autoan-
tibodies directed against nuclear antigens and a dysregulated 
immune response. The etiology of lupus remains unknown, 
although both genetic and epigenetic mechanisms have been 
shown to contribute to disease pathogenesis (1,2).
DNA methylation plays a critical role in the pathogene-
sis of lupus (3). Abnormal DNA methylation patterns have been 
described in multiple immune cell types isolated from lupus 
patients, and a role for genetic–epigenetic interaction in the patho-
genesis of lupus has been suggested (4). Furthermore, abnormal 
DNA methylation patterns in lupus have been shown to contribute 
to clinical heterogeneity, disease variability between ethnicities, 
and lupus flare and remission (4).
EZH2 induces H3K27me3 and is the catalytic compo-
nent of the highly conserved polycomb regressive complex 
2. Our group previously demonstrated that increased disease 
activity in lupus patients is characterized by an early epige-
netic shift in naive CD4+ T cells that precedes CD4+ T cell 
differentiation and effector T cell transcriptional activity (5). We 
provided evidence that this epigenetic shift is likely induced 
by EZH2 overexpression as a result of down- regulation of 
microRNA- 101 (miR- 101) and miR- 26a, in addition to showing 
that EZH2 overexpression mediates increased T cell adhesion 
in lupus due to EZH2- induced demethylation and transcrip-
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tional derepression of the junctional adhesion molecule A 
(JAM- A) (5,6).
EZH2 overexpression has been linked to increased inva-
siveness in a number of malignancies, and EZH2 inhibitors are 
currently being evaluated in clinical trials for cancer therapy (7). 
Our findings indicate that inhibiting EZH2 might have therapeutic 
potential in lupus, suggesting the possibility of pharmacologic 
repurposing of EZH2 inhibitors as a therapeutic option. In this 
study, we first examined EZH2 expression patterns in other 
immune cell types isolated in the peripheral blood from lupus 
patients. We then tested the effects of using 3′- deazaneplanocin 
(DZNep), an EZH2 inhibitor, in the lupus- prone MRL/lpr mouse 
model. DZNep is an S- adenosylhomocysteine hydrolase inhibitor 
that inactivates methyltransferase activity through feedback inhi-
bition by accumulation of S- adenosylhomocysteine (8). DZNep 
has also been shown, by us and others, to decrease EZH2 levels 
(6,7). In the current study, we utilized both preventative and ther-
apeutic approaches of administering DZNep to MRL/lpr mice. 
Our findings provide robust preclinical evidence supporting the 
potential use of EZH2 inhibitors in lupus, paving the way for 
repurposing EZH2 inhibitors in clinical trials.
MATERIALS AND METHODS
EZH2 expression in B cells, monocytes, and neutro-
phils in lupus patients. We recruited a total of 6 lupus patients 
(mean ± SEM age 46.2 ± 5.4 years, range 32–61 years) and 6 
healthy controls (mean ± SEM age 44.5 ± 5.8 years, range 30–63 
years). All lupus patients fulfilled the American College of Rheu-
matology classification criteria for SLE (9). The mean SLE Dis-
ease Activity Index score (10) score for lupus patients was 2, with 
a median of 1 (range 0–6) (see Supplementary Table 1, on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40931/ abstract). Lupus patients receiving cyclo-
phosphamide or methotrexate were excluded from the study. All 
subjects provided written informed consent approved by the Insti-
tutional Review Board of the University of Michigan.
Peripheral whole blood was collected from each study sub-
ject, and erythrocytes in blood samples were lysed with RBC Lysis 
Buffer (eBioscience). Remaining whole blood cells were incubated 
with Human Seroblock (Bio- Rad) in Cell Staining Buffer (BioLegend) 
to block nonspecific Fc receptor binding of Ig, and extracellularly 
stained with the following antibodies: allophycocyanin (APC)–Cy7–
conjugated anti- CD14 (clone 63D3; BioLegend), phycoerythrin 
(PE)–conjugated mouse anti- human CD16b (clone CLB- gran11.5; 
BD Biosciences), and APC- conjugated anti- CD19 (clone HIB19; 
BioLegend). Afterward, cells were fixed with Fixation Buffer (Bio-
Legend), permeabilized with Intracellular Staining Permeabilization 
Wash Buffer (BioLegend), and subsequently stained with fluores-
cein isothiocyanate (FITC)–conjugated anti- EZH2 (clone REA907; 
Miltenyi Biotec) or with corresponding isotype control, REA Con-
trol (I) antibody (clone REA293; Miltenyi Biotec). Stained cells were 
then analyzed by flow cytometry using an iCyt Synergy SY3200 
Cell Sorter (Sony Biotechnology) and FlowJo software, version 
10.0.7. An example of the gating strategy to determine B cells, 
monocytes, and neutrophils is shown in Supplementary Figure 1 
(http://onlin elibr ary.wiley.com/doi/10.1002/art.40931/ abstract), 
based on forward scatter (FSC) versus side scatter (SSC) and 
positive expression of their respective markers. The expression of 
EZH2 was measured by the median fluorescence intensity (MFI) of 
EZH2 antibody minus the MFI of its isotype control.
GEO data analysis. Analysis of EZH2 messenger RNA 
(mRNA) expression levels between lupus patients and healthy 
controls (in whole blood cells, CD4+ T cells, and CD19+ B cells) 
was performed using data sets downloaded from the GEO data-
base (accession nos. GSE72509 and GDS4185). These data sets 
have previously been described in detail (11,12).
Mice and treatments. Eight- week- old female MRL/lpr 
mice (no. 000485; The Jackson Laboratory) were acclimatized for 2 
weeks prior to study commencement and maintained in pathogen- 
free conditions. There were 2 model types in which DZNep (Cay-
man Chemical) was administered: a preventative model (DZNep/
DZNep) with DZNep treatments that began on day 0 of the study 
in 10- week- old mice and a therapeutic treatment model (vehicle/
DZNep) with DZNep treatments that began on day 28 of the study 
in 14- week- old mice. A vehicle- only group was also included as 
control. Mice were treated with either vehicle or DZNep (2 mg/
kg) by intraperitoneal injection. DZNep was solubilized in DMSO 
and diluted in phosphate buffered saline (PBS) prior to injection 
(final DMSO concentration in PBS was 10%). In the vehicle con-
trol group, mice received daily injections of vehicle control for 35 
days and were switched to biweekly (Monday and Thursday) dos-
ing until day 98. A similar regimen was used in the DZNep/DZNep 
prevention model group, in which mice received DZNep once daily 
from day 0 to day 35 and were then switched to twice- weekly 
dosing for the remainder of the study. In the vehicle/DZNep ther-
apeutic treatment group, animals received vehicle once daily from 
day 0 to day 27. On day 28, mice in this group were switched to a 
daily dose of DZNep until day 63; from day 64 onward, the dosing 
frequency changed to twice weekly. Animals were monitored and 
weighed daily throughout the study. This study was performed at 
Biomodels, an AAALAC- accredited facility, and approved by the 
Biomodels Institutional Animal Care and Use Committee.
Assessment of lupus nephritis and kidney damage. 
Kidneys were harvested on day 98 of the study, fixed in formalin, 
and sections were cut and stained with either hematoxylin and 
eosin or periodic acid–Schiff (PAS). Glomerulonephritis, cres-
cent formation, and necrosis in kidneys were scored clinically by 
a pathologist who was blinded with regard to the experimental 
group. Approximately 125 glomeruli in each PAS- stained slide 
were counted. Glomeruli were categorized as having crescents, 
EZH2 INHIBITION BENEFITS MRL/lpr MICE |      1683
fibrinoid necrosis, acute glomerulitis, mesangial hypercellular-
ity, segmental glomerulosclerosis, global glomerulosclerosis, or 
normal architecture. The presence of pseudothrombi, interstitial 
nephritis, and arteritis was also noted.
Urine was collected every 2 weeks beginning 2 weeks prior 
to day 0 of the study. Urine albumin and creatinine concentra-
tions were measured using enzyme- linked immunosorbent assay 
(ELISA) kits from Alpha Diagnostic and R&D Systems, respectively, 
and were then used to calculate the urine albumin:creatinine ratio.
Quantification of serum and plasma antibodies. 
Every 2 weeks, serum was collected by retroorbital bleed using 
serum separator tubes. On day 98 of the study, plasma was 
collected from all of the animals, while serum was collected in a 
portion of the DZNep/DZNep-treated mice and all of the vehicle/
DZNep-treated mice. Anti–double- stranded DNA (anti- dsDNA) 
antibody titers in serum or plasma (day 98 only) were determined 
using ELISA (Alpha Diagnostic).
Spleen and lymph node weight. Spleen and lymph 
nodes (submaxillary, thoracic, axillary, renal, and mesenteric) were 
excised on day 98 of the study, trimmed of extra fat and connec-
tive tissue, weighed, and photographed. The average weight of all 
lymph nodes in each mouse was used to represent the average 
change in lymph node weight between mouse groups.
Flow cytometric analysis of splenocytes. Each spleen 
was placed in fluorescence- activated cell sorting buffer (0.5% 
bovine serum albumin, 2 mM EDTA in PBS) and processed 
into single- cell suspension using a gentleMACS Dissociator. 
Total spleen cell counts were obtained by counting a fraction of 
the diluted cells by flow cytometry. Red blood cells were lysed 
using BD Pharm Lyse lysis buffer (BD Biosciences) prior to the 
addition of mouse FcR Blocking Reagent (Miltenyi Biotec). Cells 
were stained with the following fluorochrome- conjugated anti-
bodies: VioBlue- conjugated CD3ε (clone 17A2; Miltenyi Biotec), 
APC–Cy7–conjugated rat anti- mouse CD4 (clone GK1.5; BD Bio-
sciences), PE- conjugated rat anti- mouse CD8a (clone 53- 6.7; BD 
Biosciences), PerCP–Cy5.5–conjugated anti- mouse T cell recep-
tor β chain (TCRβ) (clone H57- 597; BioLegend), FITC- conjugated 
anti- mouse CD19 (clone 6D5; BioLegend), APC- conjugated 
CD45R (B220) (clone RA3- 6B2; Miltenyi Biotec), and PE–Cy7–
Figure 1. Analysis of EZH2 expression in human peripheral blood cells. A–C, EZH2 expression, analyzed by flow cytometry, was elevated in 
B cells (A), monocytes (B), and neutrophils (C) from lupus patients compared to controls. Values in the upper panels are the mean ± SEM. D–F, 
EZH2 mRNA levels were elevated in whole blood from lupus patients (n = 99) compared to controls (n = 18) (D), and were also elevated in B 
cells (E) and CD4+ T cells (F) from lupus patients (n = 14) compared to controls (n = 9). Symbols represent individual subjects; bars show the 
mean ± SEM. MFI = median fluorescence intensity.
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conjugated anti- mouse CD11c (clone N418; BioLegend). Stained 
cells were then analyzed by flow cytometry using a MACSQuant 
Analyzer 10 (Miltenyi Biotec) and WinList software, version 9 (Ver-
ity Software House). The following cell types were gated based on 
FSC versus SSC and positive expression of their respective mark-
ers: B cells (TCRβ−CD19+), total T cells (TCRβ+), CD4+ T cells 
(TCRβ+CD4+), CD8+ T cells (TCRβ+CD8+), and double- negative 
T cells (TCRβ+CD4−CD8−). An example of the gating strategy is 
shown in Supplementary Figure 2 (http://onlin elibr ary.wiley.com/
doi/10.1002/art.40931/ abstract).
EZH2, H3K27me3, and JAM- A expression in spleno-
cytes. To confirm that successful inhibition of EZH2 in mice was 
achieved by DZNep treatment, EZH2 and H3K27me3 levels in 
splenocytes were examined using Western blotting. Protein (20 μg) 
of protein was separated by sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis before electroblotting onto a nitrocellulose 
membrane. Blots were probed with anti- EZH2 or anti- H3K27me3 
antibodies (both from Cell Signaling Technology). β- actin (Sigma- 
Aldrich) and H3 (Cell Signaling Technology) were used as loading 
controls. Since we previously showed that JAM- A is regulated by 
EZH2 and down- regulated by DZNep in lupus CD4+ T cells (6), 
we also examined levels of JAM- A (Santa Cruz Biotechnology) in 
these cells. Densitometry was analyzed using ImageJ.
Cytokine analysis. Cytokine levels in plasma from day 98 
of the mouse study were analyzed using a Bio- Plex Pro Mouse 
Cytokine 23- plex Assay. The cytokines assayed included tumor 
necrosis factor (TNF), interferon- γ (IFNγ), interleukin- 1α (IL- 1α), IL- 
1β, IL- 2, IL- 3, IL- 4, IL- 5, IL- 6, IL- 9, IL- 10, IL- 12, IL- 12p40, IL- 13, 
IL- 17A, CCL2, RANTES/CCL5, keratinocyte- derived chemokine 
(KC)/CXCL1, eotaxin/CCL11, macrophage inflammatory protein 
1α (MIP- 1α), MIP- 1β/CCL4, granulocyte colony- stimulating factor 
(G- CSF), and granulocyte–macrophage colony- stimulating factor 
(GM- CSF).
Statistical analysis. Mann- Whitney U tests were used to 
compare the publicly available data on human EZH2 expression 
levels in whole blood, B cells, and CD4+ T cells in lupus patients 
and healthy controls. EZH2 expression , measured by flow 
cytometry, in B cells, monocytes, and neutrophils from lupus 
patients versus healthy controls was compared using an 
Figure 2. Survival improvement and reduced anti–double- stranded DNA (anti- dsDNA) antibody production in 3′- deazaneplanocin (DZNep)–
treated MRL/lpr mice. A, Schematic representation of preventative and therapeutic treatment models. DZNep treatment in the preventative 
group (DZNep/DZNep) began when mice were 10 weeks old, 2 weeks prior to typical disease onset. The therapeutic group (vehicle/DZNep) 
received DZNep treatment 2 weeks after disease onset, when mice were 14 weeks old. B, Schematic representation of treatment regimens. 
The DZNep/DZNep group received DZNep once daily for 35 days and on day 36 was switched to a twice- weekly regimen until the end of the 
study. The control group was treated at the same times as the DZNep/DZNep group, with vehicle administered instead of DZNep. The vehicle/
DZNep group received vehicle once daily for 27 days, then was switched to daily dosing of DZNep from day 28 through day 63. On day 64, 
DZNep dosing was reduced to twice weekly until the end of the study. C, Survival curves of the vehicle, DZNep/DZNep, and vehicle/DZNep 
groups (n = 15 per group at start). D, Anti- dsDNA antibody levels. Values are the mean ± SEM.
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unpaired t- test, or Mann- Whitney U test when normality could 
not be assumed. Survival analysis was performed using the 
Mantel- Cox log- rank test. All other mouse data were evaluated 
by one- way analysis of variance, or Kruskal- Wallis test when 
normality could not be assumed, using Dunn’s multiple compar-
ison test to compare the preventative and therapeutic groups to 
the control group. All statistical analyses were performed using 
GraphPad Prism, version 7. Data are presented as the mean ± 
SEM. P values less than 0.05 were considered significant.
RESULTS
EZH2 expression in lupus. We previously showed that 
EZH2 is up- regulated in lupus CD4+ T cells and that T cell overex-
pression of EZH2 plays an important role in lupus (5,6). To examine 
whether other immune cell types also overexpress EZH2 in lupus, 
we assessed EZH2 expression using flow cytometry in peripheral 
blood B cells, monocytes, and neutrophils from lupus patients and 
compared it to that in healthy controls. EZH2 expression, as meas-
ured by MFI, was significantly elevated in B cells, monocytes, and 
neutrophils of lupus patients compared to matched controls (P 
< 0.05) (Figures 1A–C). Using previously published gene expres-
sion profiles available in GEO, we analyzed EZH2 mRNA levels in 
whole blood (GEO accession no. GSE72509) and freshly isolated 
lymphocyte subsets (GEO accession no. GDS4185) from lupus 
patients and healthy controls. EZH2 mRNA levels in whole blood 
from lupus patients were significantly higher than those in healthy 
controls (P < 0.01) (Figure 1D). Similarly, EZH2 expression was 
significantly elevated in the freshly isolated B cells and CD4+ T 
cells from lupus patients compared to controls (P < 0.05) (Fig-
ures 1E and F).
Effect of EZH2 inhibition on mortality and autoanti-
body production in MRL/lpr mice. To examine whether inhi-
bition of EZH2 is beneficial in lupus- like disease, an EZH2 inhibitor, 
DZNep, was administered to MRL/lpr mice (Figures 2A and B). As 
shown in Figure 2C, mice that received only vehicle had 33.3% mor-
tality by the end of the study on day 98 (mice were 24 weeks old). 
Mice in the preventative group had 100% survival, while there was 
6.67% mortality in the therapeutic group by the end of the study. 
There was a significant difference in the mortality rates between the 
DZNep/DZNep-treated mice and the controls (P < 0.05).
Anti- dsDNA antibody levels were significantly lower in the 
preventative group by day 14, 2 weeks after DZNep treatment 
began in this group, and anti- dsDNA antibody levels remained 
significantly lower throughout the duration of the study (P < 
0.001) (Figure 2D). By day 56, the anti- dsDNA titers were sig-
nificantly lower in mice in the therapeutic group compared to 
the vehicle control group (P < 0.05) and remained significantly 
lower for the next 28 days, though there was not a significant 
difference detected at the final time point (Figure 2D). Although 
plasma was used instead of serum for quantification of anti- 
Figure 3. Reduced renal involvement in 3′- deazaneplanocin (DZNep)–treated MRL/lpr mice. A–C, The percentage of total glomeruli with 
glomerulonephritis (A), crescent formation (B), and necrosis (C) in the kidneys of mice in the vehicle, DZNep/DZNep, and vehicle/DZNep 
groups. D, Photomicrographic representation of renal damage. D1, Glomerulus with glomerulomegaly and cellular crescent (arrow) from a 
mouse in the control group. D2, Acute global glomerulitis and segmental fibrinoid necrosis (arrow) from a mouse in the control group. D3, 
Normal- appearing glomerulus from a mouse in the DZNep/DZNep group. D4, Glomerulus with mesangial hypercellularity from a mouse in the 
vehicle/DZNep group. Periodic acid–Schiff stained (D1, D3, and D4) or hematoxylin and eosin stained (D2); original magnification × 400. E, Urine 
albumin:creatinine ratios (UACRs) in the vehicle, DZNep/DZNep, and vehicle/DZNep groups. Values in A, B, C, and E are the mean ± SEM.
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dsDNA on day 98, the levels were similar to those measured 
in serum (data not shown). Our results showed that DZNep 
improved survival in the MRL/lpr mice and significantly reduced 
the production of anti- dsDNA antibodies 2–4 weeks following 
daily dosing of DZNep.
Effect of DZNep treatment on renal involvement. 
To assess the effect of DZNep on renal damage, glomerulone-
phritis, crescent formation, and necrosis were assessed in each 
mouse on day 98 of the study. Development of glomerulonephri-
tis and crescents was significantly reduced in both the preventa-
tive and therapeutic groups compared to the control group (P < 
0.05)  (Figures 3A and B). There also was a significant reduction 
in glomerular necrosis in the preventative group compared to the 
control group (P < 0.01), but the difference observed between 
the control group and the therapeutic group was not statisti-
cally significant (Figure 3C). Representative photomicrographs of 
glomeruli from each treatment group are depicted in Figure 3D. 
Overall, the number of glomeruli with no pathologic abnormality 
was significantly higher in the preventative group compared to the 
control group (mean ± SEM 65.8 ± 4.7% versus 31.6 ± 7.2%; 
P < 0.01) (Supplementary Figure 3, http://onlin elibr ary.wiley.com/
Figure  4. Reduced splenomegaly and lymphadenopathy in 3′- deazaneplanocin (DZNep)–treated MRL/lpr mice. A, Weight of individual 
spleens, and representative photographs. B, Mean weight of lymph nodes from all sites, and representative photographs of renal lymph 
nodes. C, Expression of EZH2, junctional adhesion molecule A (JAM- A), and H3K27me3 in splenocytes, examined by Western blotting (WB). 
Representative blots from 3 mice per treatment group are shown. A total of 8 samples per group were analyzed for densitometry. In A and B 
(left panels) and C (lower panels), symbols represent individual mice; bars show the mean ± SEM.
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doi/10.1002/art.40931/ abstract). To monitor the progression of 
kidney involvement, proteinuria was analyzed using albumin:cre-
atinine ratios that were calculated every 2 weeks throughout the 
study. These ratios were significantly lower in the preventative 
group (by day 14) and the therapeutic group (by day 42) com-
pared to the control group (P < 0.01) (Figure 3E). In both treatment 
groups, the albumin:creatinine ratio remained significantly lower 
throughout the remainder of the study. Overall, DZNep treatment, 
both preventative and therapeutic, significantly reduced lupus 
nephritis and renal damage in MRL/lpr lupus- prone mice.
Reduced splenomegaly and lymphadenopathy with 
DZNep. MRL/lpr mice develop progressive enlargement of the 
spleen and lymph nodes due to lymphoproliferation that is char-
acteristic of the strain. The spleens from vehicle- treated mice 
weighed significantly more than those from mice in the preventa-
tive and therapeutic groups (P < 0.001) (Figure 4A). The mean 
weight of lymph nodes from all sites (submaxillary, thoracic, axil-
lary, renal, and mesenteric) in both the preventative and therapeu-
tic groups was significantly lower than that of the control group 
(P < 0.0001) (Figure  4B and Supplementary Figure 4, http://
onlin elibr ary.wiley.com/doi/10.1002/art.40931/ abstract). DZNep 
appeared to be efficacious in reducing the progression of spleno-
megaly and lymphadenopathy in MRL/lpr mice.
Reduced EZH2, H3K27me3, and JAM- A with DZNep. 
In splenocytes, DZNep treatment in both the preventative 
and therapeutic groups significantly reduced both EZH2 and 
H3K27me3 levels, suggesting that the dosing regimen we 
adopted was effective in inhibiting EZH2 (P < 0.05; n = 8) 
(Figure 4C). In addition, JAM- A levels in splenocytes were sig-
nificantly reduced in the preventative group (P < 0.05), while 
these reductions were only marginally significant in the thera-
peutic group due to an outlier (P = 0.08). These results suggest 
that EZH2 regulates JAM- A expression, and manipulation of 
EZH2 expression by DZNep down- regulates JAM- A, similar to 
what we previously showed in CD4+ T cells in lupus patients 
(6).
Reduced lymphoproliferation with DZNep. Using 
flow cytometry, we further explored the effect of EZH2 inhibi-
tion on lymphoproliferation in MRL/lpr mice by analyzing differ-
ences between groups of T cell and B cell populations. Both 
the preventative and therapeutic groups showed reduced 
numbers of total splenocytes, total T cells (TCRβ+), CD8+ T 
cells (TCRβ+CD8+), and double- negative T cells (TCRβ+CD4−
CD8−), compared to the control group (P < 0.01) (Figures 5A–C). 
The total number of CD4+ T cells (TCRβ+CD4+) was signifi-
cantly decreased in the therapeutic group compared to the con-
trol group (P < 0.01) (Figure 5C). In addition, DZNep treatment 
in both the preventative and therapeutic groups significantly 
reduced the percentage of double- negative T cells, while sig-
nificantly increasing the percentage of CD4+ and CD8+ T cells 
by the end of the study, compared to the control group (P ≤ 
0.0001) (Figure 5D). The observed shift in T cell populations and 
the reduction in total number of T cells suggests that DZNep 
reduces both T cell hyperproliferation and the generation of 
pathogenic double- negative T cells in MRL/lpr mice.
There was no difference in the total number of B cells 
(TCRβ−CD19+) between any of the groups (Figure 5E). However, 
we observed that the B cell percentage among total splenocytes 
was significantly greater in both the preventative and therapeutic 
groups compared to the control group (P ≤ 0.0001) (Figure 5F).
Cytokine levels. To further characterize the effect of EZH2 
inhibition in MRL/lpr mice, we analyzed the differential expression 
of plasma cytokine levels on day 98. Levels of IL- 3, IL- 1β, IL- 9, 
IL- 13, IL- 6, IL- 4, G- CSF, GM- CSF, and MIP- 1α were undetect-
able. No significant differences were observed between DZNep 
treatment groups and controls for IL- 2, IL- 5, IL- 1α, IL- 17A, and 
eotaxin/CCL11 (data not shown). However, there was a signifi-
Figure  5. Reduced lymphoproliferation in 3′- deazaneplanocin 
(DZNep)–treated MRL/lpr mice. A and B, Total numbers of 
splenocytes (A) and T cells (B) in the DZNep/DZNep and vehicle/
DZNep groups compared to controls. C and D, Total numbers (C) 
and percentages (D) of double- negative (DN) T cells, CD4+ T cells, 
and CD8+ T cells in mice in each treatment group. Values are the 
mean ± SEM. E and F, Total numbers of B cells (E) and percentages 
of B cells among splenocytes (F) in mice in each treatment group. 
In A, B, E, and F, symbols represent individual mice; bars show the 
mean ± SEM.
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cant reduction in plasma levels of TNF, IFNγ, CCL2, RANTES/
CCL5, IL- 10, KC/CXCL1, IL- 12, IL- 12p40, and MIP- 1β/CCL4 in 
both the preventative and therapeutic groups compared to the 
control group (Figure 6).
DISCUSSION
Our previous findings suggested that EZH2 plays an impor-
tant role in lupus (5,6). We have reported that naive CD4+ T cells 
in lupus patients showed higher expression levels of EZH2 than 
those in healthy controls, and this up- regulation is critical for T cell 
adhesion, as inhibition of EZH2 by DZNep can normalize the ability 
of lupus CD4+ T cells to adhere to endothelial cells (6). In the pres-
ent study, we further examined the expression of EZH2 in other 
cell types and showed that EZH2 was significantly up- regulated in 
B cells, monocytes, and neutrophils in lupus patients. These data 
prompted us to investigate whether inhibition of EZH2 would be 
beneficial for lupus treatment. Indeed, in MRL/lpr mice, DZNep 
treatment, administered in either a preventative or a therapeutic 
protocol, improved survival and reduced autoantibody production. 
In addition, the therapeutic effects of DZNep appeared rapidly, with 
lowered anti- dsDNA antibody levels and albumin:creatinine ratio 
evident 14 days after the first dose.
The improvement in survival observed in DZNep- treated 
mice is likely due, in part, to a reduction in renal involvement. 
DZNep treatments appeared to prevent the progression of renal 
damage, as evidenced by a relatively stable albumin:creatinine 
ratio in DZNep- treated mice. Renal damage was also assessed 
at the end of the study by histopathologic examination. We 
observed a significant reduction in glomerulonephritis and cres-
cent formation in both DZNep treatment groups and a signifi-
cant reduction in glomerular necrosis in the preventative group 
(DZNep/DZNep) compared to the control group, by the end of 
the study. The development of nephritis is indicative of severe 
disease in lupus patients and is an important predictor of mor-
bidity and mortality. Based on our finding that DZNep treatment 
effectively reduced renal involvement in MRL/lpr mice, an EZH2 
inhibitor could prove similarly therapeutic for lupus patients.
The MRL/lpr mouse model is a lymphoproliferative model 
characterized by T cell and B cell dysregulation (13). The infiltra-
tion of double- negative T cells, in addition to an overall hyper-
proliferation of T cell populations, contributes significantly to the 
Figure 6. Decreased levels of plasma cytokines in 3′- deazaneplanocin (DZNep)–treated MRL/lpr mice. There was a significant reduction in 
plasma levels of tumor necrosis factor (TNF), interferon- γ (IFNγ), monocyte chemotactic protein 1 (MCP- 1)/CCL2, RANTES/CCL5, interleukin- 10 
(IL- 10), keratinocyte- derived chemokine (KC)/CXCL1, IL- 12, IL- 12p40, and macrophage inflammatory protein 1β (MIP- 1β)/CCL4 in both the 
DZNep/DZNep and vehicle/DZNep groups compared to the control group. Symbols represent individual mice; bars show the mean ± SEM.
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observed splenomegaly and lymphadenopathy in MRL/lpr mice 
(13,14). We observed a significant reduction in spleen and lymph 
node weight in both groups of mice treated with DZNep. A sig-
nificant decrease in the total number of splenocytes in DZNep- 
treated groups was also observed, suggesting a reduction in 
lymphoproliferation. While DZNep treatment in both groups 
reduced the total number of T cells, CD4+ T cells, and CD8+ 
T cells, the reduction in CD4−CD8− (double-negative) T cells is 
of particular interest. Double- negative T cells represent a path-
ogenic T cell subset in lupus likely derived from CD8+ T cells 
(15). These cells contribute to the production of autoantibodies, 
produce significant amounts of inflammatory cytokines includ-
ing IL- 17 and IFNγ, and contribute to renal damage as they 
accumulate in the kidneys of lupus patients (15–18). Inhibition 
of EZH2 with DZNep significantly reduced the total number of 
pathogenic double- negative T cells in MRL/lpr mice. Indeed, the 
significant reduction in double- negative T cell numbers observed 
with DZNep treatment caused significant elevation in the per-
centages of single- positive T cells (CD4+ and CD8+ T cells). 
We speculate that the reduction of pathogenic double- negative 
T cells in the DZNep- treated groups likely contributed to the 
observed reduction in renal damage and levels of circulating 
autoantibodies.
Production of cytokines and chemokines is important in lupus 
pathogenesis and tissue damage in lupus patients. We observed 
reduced concentrations of TNF, IFNγ, CCL2, RANTES/CCL5, IL- 
10, IL- 12, IL- 12p40, and MIP- 1β/CCL4 in the plasma from mice 
in the DZNep- treated groups compared to controls. All of these 
cytokines and chemokines have been reported to be elevated 
in lupus patients (19–23). Chemokines such as RANTES/CCL5, 
monocyte chemotactic protein 1/CCL2, and MIP- 1β/CCL4 con-
tribute to lupus pathogenesis by recruiting leukocytes and other 
effector cells to inflamed tissues, causing damage (19–21). IL- 10 
and TNF have been shown to be up- regulated in lupus patients 
experiencing renal involvement, and their levels correlate with dis-
ease activity (19,22). IFNγ has been found to contribute to the 
development of lupus through promotion of autophagy in lupus 
T cells, and potentially the persistence of pathogenic T cell sub-
sets (22). Dysregulation of IL- 12 has been reported in patients with 
lupus (24), and promising results were seen in a recent phase II 
trial in which ustekinumab, which targets IL- 12p40, was added to 
the standard of care in lupus patients (25).
We have previously demonstrated that EZH2 might mediate 
a pathogenic effect in lupus by altering T cell DNA methylation pat-
terns and up- regulation of the adhesion molecule JAM- A in CD4+ 
T cells (5,6). In the present study, we showed that DZNep treat-
ment in MRL/lpr mice also down- regulates JAM- A in splenocytes, 
suggesting that its beneficial effect in these animals might be due, 
in part, to inhibition of lymphocyte adhesion and extravasation. 
Because the Notch signaling pathway regulates effector T cell 
survival and function, including cytokine production (26–28), we 
speculated that another potential  mechanism of action for EZH2 
in lupus might involve the Notch signaling pathway. EZH2 has 
been shown to inhibit T cell Notch repressors, promoting Notch 
activation and thus effector T cell polyfunctionality and survival 
(29). The Notch pathway is also critical in B cells and monocytes 
(30–34), which were characterized by EZH2 overexpression in 
lupus in our study.
Several limitations to this study are worth noting. We utilized 
a systemic approach to inhibit EZH2. While this approach allowed 
for assessment of the overall effect of EZH2 inhibition (which would 
be important if a clinical trial using EZH2 inhibitors were to be con-
ducted in lupus patients), it did not allow for the identification of 
the specific cell types or pathways mediating the therapeutic effect 
of EZH2 inhibition in this lupus- prone mouse model. In addition, 
as noted above, although DZNep is a prototype EZH2 inhibitor, 
it inhibits methyltransferase activity, and therefore, nonspecific 
effects of DZNep cannot be ruled out. Future studies focused on 
characterizing the effects of EZH2 inhibition in specific cell types in 
vivo and on utilizing other more specific EZH2  inhibitors are war-
ranted.
In summary, we have demonstrated that EZH2 is overex-
pressed in multiple immune cell types in lupus patients. Inhibition 
of EZH2 is associated with abrogation of lupus- like disease in 
MRL/lpr mice. Our data suggest that inhibiting EZH2 might pro-
vide a novel therapeutic approach for lupus patients.
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